NuCana plc

DB:N04 Stock Report

Market Cap: €178.4k

NuCana Management

Management criteria checks 3/4

NuCana's CEO is Hugh Griffith, appointed in Mar 2008, has a tenure of 17.17 years. total yearly compensation is £661.17K, comprised of 90.2% salary and 9.8% bonuses, including company stock and options. directly owns 0.84% of the company’s shares, worth €1.49K. The average tenure of the management team and the board of directors is 5 years and 5.8 years respectively.

Key information

Hugh Griffith

Chief executive officer

UK£661.2k

Total compensation

CEO salary percentage90.24%
CEO tenure17.2yrs
CEO ownership0.8%
Management average tenure5yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Hugh Griffith's remuneration changed compared to NuCana's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024UK£661kUK£597k

-UK£19m

Sep 30 2024n/an/a

-UK£26m

Jun 30 2024n/an/a

-UK£28m

Mar 31 2024n/an/a

-UK£27m

Dec 31 2023UK£975kUK£574k

-UK£28m

Sep 30 2023n/an/a

-UK£35m

Jun 30 2023n/an/a

-UK£33m

Mar 31 2023n/an/a

-UK£31m

Dec 31 2022UK£1mUK£552k

-UK£32m

Sep 30 2022n/an/a

-UK£30m

Jun 30 2022n/an/a

-UK£34m

Mar 31 2022n/an/a

-UK£39m

Dec 31 2021UK£907kUK£531k

-UK£41m

Sep 30 2021n/an/a

-UK£39m

Jun 30 2021n/an/a

-UK£40m

Mar 31 2021n/an/a

-UK£36m

Dec 31 2020UK£920kUK£551k

-UK£31m

Sep 30 2020n/an/a

-UK£26m

Jun 30 2020n/an/a

-UK£22m

Mar 31 2020n/an/a

-UK£20m

Dec 31 2019UK£828kUK£498k

-UK£21m

Sep 30 2019n/an/a

-UK£17m

Jun 30 2019n/an/a

-UK£16m

Mar 31 2019n/an/a

-UK£13m

Dec 31 2018UK£786kUK£467k

-UK£14m

Compensation vs Market: Hugh's total compensation ($USD876.75K) is above average for companies of similar size in the German market ($USD491.43K).

Compensation vs Earnings: Hugh's compensation has been consistent with company performance over the past year.

CEO

Hugh Griffith (56 yo)

17.2yrs

Tenure

UK£661,165

Compensation

Mr. Hugh Stephen Griffith is Founder of NuCana plc (formerly, NuCana BioMed Limited) and has been its Chief Executive Officer since March 2008. Mr. Griffith was also the Chief Executive Officer at Alida Ca...

Leadership Team

NamePositionTenureCompensationOwnership
Hugh Griffith
Founder17.2yrsUK£661.17k0.84%
€ 1.5k
David Harrison
Head of Translational Medicine & Studies7.4yrsno data0%
€ 0
Jeffrey Bloss
Chief Medical Officer3.8yrsno data0.014%
€ 24.7
Theresa Bruce
Senior Vice President of Clinical Operations5.3yrsno datano data
Elisabeth Oelmann
Senior Vice President of Medical & Clinical Development4.6yrsno datano data
Gordon Kennovin
Senior VP of CMC & Development1.3yrsno datano data
Stuart Grant
Senior Vice President of Regulatory Affairs1.3yrsno datano data
Martin Quinn
Company Secretary7.8yrsno datano data

5.0yrs

Average Tenure

64yo

Average Age

Experienced Management: N04's management team is considered experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hugh Griffith
Founder17.2yrsUK£661.17k0.84%
€ 1.5k
Andrew Kay
Independent Non-Executive Chairman4.4yrsUK£79.72k0%
€ 0
Martin Christopher Mellish
Independent Non-Executive Director15.4yrsUK£48.38k0.022%
€ 39.1
Balaji Muralidhar
Independent Non-Executive Director4.7yrsUK£29.25k0.00036%
€ 0.6
Elliott Levy
Independent Director3.5yrsUK£54.91k0.012%
€ 22.1
Cyrille Raymond Leperlier
Independent Non Executive Director7yrsUK£65.90k0%
€ 0

5.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: N04's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/14 13:37
End of Day Share Price 2025/05/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NuCana plc is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yigal NochomovitzCitigroup Inc
Eun Kyung YangJefferies LLC
Joseph CatanzaroPiper Sandler Companies